Andina III and EMMAC Life Sciences Limited said today they have mutually terminated negotiations regarding a proposed business combination. The parties signed a non-binding letter of intent on July 22, in which EMMAC was expected to trade on the NASDAQ. Both sides cited “challenging global economic conditions” among the reasons for terminating the deal. EMMAC bills itself as Europe’s largest independent cannabis company. Andina shareholders last week approved an extension of the SPAC’s deadline to close a deal. Andina was initially capitalized with a $100M IPO. Read more.
Related Posts
Crucible Acquisition III Files for $350M IPO
The SPAC will target companies in the software technology industry with an enterprise valuation between $1.8 billion and $3.0 billion, prioritizing cloud-based recurring revenue business models.
Flame Acquisition Adds Substantially to PIPE for Sable Deal
The merger was announced in November 2022 at an $883 million enterprise value.
Stellaris Growth Acquisition Files for $128M IPO
The SPAC will target a business focusing on the data centers and internet technology sectors.
Thoma Bravo and ironSource Complete $11.1B Deal
The transaction included $2.15 billion in cash proceeds, including an oversubscribed PIPE of $1.3 billion and funds from the SPAC's trust account.